Journal
CLINICAL CANCER RESEARCH
Volume 20, Issue 23, Pages 5866-5868Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-1543
Keywords
-
Categories
Funding
- NCI NIH HHS [R37 CA075059, R01 CA075059, CA-R37-075059] Funding Source: Medline
Ask authors/readers for more resources
Activated p38 MAPK alpha (pp38 alpha) is a good prognostic marker in pancreatic ductal adenocarcinoma that could be used to personalize therapy. pp38 alpha suppresses JNK-mediated proliferation, both in vitro and in vivo. These findings support the testing of combination therapies that include JNK targeting and/or suppressing negative regulators of pp38 alpha. (C) 2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
